Ashton Thomas Private Wealth’s United Therapeutics UTHR Stock Holding History

Ashton Thomas Private Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Sell	438 -1,557	-78%	-$877K	﹤0.01%	1081
2026 Q1	$1.18M	Buy	1,995 +41	+2%	+$20.4K	0.03%	485
2025 Q4	$952K	Sell	1,954 -58	-3%	-$27K	0.02%	506
2025 Q3	$843K	Sell	2,012 -7,913	-80%	-$2.66M	0.02%	511
2025 Q2	$2.85M	Buy	9,925 +5,261	+113%	+$1.57M	0.1%	217
2025 Q1	$1.44M	Buy	4,664 +1,844	+65%	+$632K	0.05%	314
2024 Q4	$995K	Buy	+2,820	New	+$1.04M	0.04%	380
2024 Q3	–	Sell	-37	Closed	-$11.8K	–	1777
2024 Q2	$11.8K	Buy	+37	New	+$9.79K	﹤0.01%	1290

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Ashton Thomas Private Wealth's UTHR Position: Q2 2026 in Review

Ashton Thomas Private Wealth reduced its United Therapeutics (UTHR) stake by 78% in Q2 2026, selling an estimated $877K and leaving 438 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #1081.

Ashton Thomas Private Wealth first reported a position in UTHR in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.85M in Q2 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Ashton Thomas Private Wealth held 438 shares of United Therapeutics worth $237K as of Q2 2026.
Ashton Thomas Private Wealth sold 1,557 United Therapeutics shares in Q2 2026, an estimated $877K.
United Therapeutics made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q2 2026, its #1081 holding.
Ashton Thomas Private Wealth first reported a position in United Therapeutics in Q2 2024 and has held it in 8 quarters since.
Ashton Thomas Private Wealth's United Therapeutics position peaked at $2.85M in Q2 2025.
875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.